The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage II-III colorectal cancer

Surg Today. 2023 Aug;53(8):890-898. doi: 10.1007/s00595-023-02644-6. Epub 2023 Jan 27.

Abstract

Purpose: To investigate a prognostic score for stage II-III colorectal cancer (CRC) based on post-CEA and pT4 levels.

Methods: Two cohorts of stage II-III CRC patients who underwent curative surgery between 2011 and 2017 were included. The prognostic score (T-CEA score) was calculated as follows: T-CEA-0, post-CEA ≤ 5 ng/mL and pT1-3; T-CEA-1, post-CEA > 5 ng/mL or pT4; T-CEA-2, post-CEA > 5 ng/mL and pT4.

Results: The T-CEA scores of the 587 patients were as follows: T-CEA-0 (n = 436; 74%), T-CEA-1 (n = 129; 22%), and T-CEA-2 (n = 10; 2%). The 5-year recurrence-free survival (RFS) rates of the T-CEA-0, 1, and 2 groups were 80.3%, 54.8%, and 0%, respectively (P < 0.01), and the 5-year overall survival (OS) rates were 90.9%, 74.2%, and 0%, respectively (T-CEA-0 vs T-CEA-1: P < 0.01, T-CEA-1 vs T-CEA-2: P = 0.04). Multivariate analysis revealed that an elevated T-CEA score of 1 or 2 was a significant risk factor for poor RFS (HR: 2.89, P < 0.01) and OS (HR: 2.85, P < 0.01).

Conclusion: The T-CEA score is a reliable and convenient prognostic score for stage II-III CRC.

Keywords: Pathological T4; Postoperative CEA; Prognostic score; Stage II–III colorectal cancer; T-CEA score.

MeSH terms

  • Carcinoembryonic Antigen*
  • Colorectal Neoplasms* / pathology
  • Humans
  • Prognosis
  • Retrospective Studies
  • Risk Factors

Substances

  • Carcinoembryonic Antigen